The sell-off in Moderna Inc
MRNA 15.64% stock is a phenomenal buying opportunity for investors with a long-term outlook, Short Hills Capital's Steve Weiss said Wednesday on CNBC's "Fast Money Halftime Report."
Moderna got ahead of itself, as momentum stocks often do, Weiss said —yet he said the fundamentals are improving as the stock trades lower.
New data suggests Moderna's COVID-19 vaccine may be superior to Pfizer Inc's PFE 3.9% vaccine, he said.
Weiss told CNBC he sold a portion of his position after the stock rallied Tuesday, but Moderna remains a "very large position" in his portfolio.
The sell-off is a buying opportunity for investors with a long-term view, he said, adding that long-term doesn't have to mean 10 years. It could be three or six months.
"The stock is still the cheapest stock I own. They are still going to earn $30 this year, which puts them at 10 times [earnings] growing exponentially with a technology platform, in my view, that is comparable to Amazon.com Inc
AMZN 0.86% or Apple Inc AAPL 0.18%," Weiss said.
"This story is just beginning."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.